Bioethics and post-approval research in translational science

American Journal of Bioethics

Volumn 10, Issue 8, 2010, Pages 35-37

  Chen, Jiin Yu ^a   Carter, Michele ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ROSIGLITAZONE;

ARTICLE; CLINICAL TRIAL; DRUG APPROVAL; DRUG INDUSTRY; ETHICS; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN EXPERIMENT; PHASE 4 CLINICAL TRIAL; TRANSLATIONAL RESEARCH; UNITED STATES;

CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE IV AS TOPIC; DRUG APPROVAL; DRUG INDUSTRY; HUMANS; HYPOGLYCEMIC AGENTS; THERAPEUTIC HUMAN EXPERIMENTATION; THIAZOLIDINEDIONES; TRANSLATIONAL RESEARCH; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77955326451     PISSN: 15265161     EISSN: 15360075     Source Type: Journal    
DOI: 10.1080/15265161.2010.494220     Document Type: Article

References (8)

1. Berlin, J. A., S. C. Glasser, and S. S. Ellenberg. 2008. Adverse event detection in drug development: Recommendations and obliga- tions beyond phase 3. American Journal of Public Health 98(8): 1366-1371.
2. Dawson, L., D. Zarin, E. Emanuel, L. Freidman, B. Chaudhari, and S. Goodman. 2009. Considering usual medical care in clinical trial design. PLoS Medicine 6(9): e1000111.
3. Glasser, S. P., M. Salas, and E. Delzell. 2007. Importance and chal- lenges of studying marketed drugs: What is a phase IV study? Common clinical research designs, registries, and self-reporting systems. Journal of Clinical Pharmacology 47: 1074-1086.
4. Moynihan, R. 2010. Rosiglitazone, marketing, and medical science. British Medical Journal 340: 785-789.
5. Nissen, S. E. 2010. The rise and fall of rosiglitazone. European Heart Journal 31: 773-776.
6. Nissen, S. E., and K.Wolski. 2007. Effect of rosiglitazone on the risk of myocardial infarction and death fromcardiovascular causes.New England Journal of Medicine 356(24): 2457-2471.
7. Sofaer, N., and N. Eyal. 2010. The diverse ethics of translational research. American Journal of Bioethics 10(8): 19-30.
8. Strom, B. L. 2006. How the US drug safety system should be changed. Journal of the American Medical Association 295(17): 2072-2075.